Draft:Alpha Teknova
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Qwerfjkl (bot) (talk | contribs) 5 seconds ago. (Update) |
Alpha Teknova is an American biotechnology company based in California, specializing in the supply of essential reagents for the
| Company type | Public |
|---|---|
| Industry | Health Care/Life Sciences |
| Founded | 1996 |
| Founder | Ted Davis |
Area served | Worldwide |
Key people | Ted Davis (Founder, Director)
Stephen Gunstream (President and CEO) Matthew Lowell (Chief Financial Officer) Damon Terrill (General Counsel and Chief Compliance Officer) Jennifer Henry (Senior Vice President of Marketing) |
| Products | Agar Plates, Microbial Culture Media, Bacterial Culture Media, Yeast And Fungal, Buffers and Reagents, Dry Powders, PCR Certified Water, Reagent Grade Water, WFI Quality Water, AAV•Tek AEX Buffer Screening Kit, AAV•Tek PCR Sample Prep Kit, AAV•Tek AAV Stabilizer |
| Revenue | US$36.684 million (2023) |
| -US$36.78 million (2023) | |
| Total assets | US$ 128.587 million (2023) |
| Total equity | US$90.036 million (2023) |
Number of employees | 211 |
| Website | https://teknova.com |
production of biopharmaceutical products. The company's patented technologies facilitate the development and delivery of custom products, including reagents and materials for bioprocessing, biomanufacturing, and molecular diagnostics. These products include cell culture media, protein and nucleic acid purification kits, and reagents used in gene therapy, mRNA therapy, genomics, and synthetic biology.[1]
History
[edit]Alpha Teknova was founded in 1996 by Ted Davis, a former scientist at Genentech, in Half Moon Bay, California[2]. Before establishing the company, Davis served as the Director of Consumables at Genomyx Inc., a company founded within Genentech. Until May 2020, he held the positions of President, CEO, and Chief Scientific Officer at Alpha Teknova. Ted Davis currently serves on the company's Board of Directors.[3][4]
In 2017, the company began the process of certifying its quality management system for medical devices to comply with ISO 13485:2016 standards. The certification was obtained on April 8, 2023, and is valid until July 25, 2026.[5]
Alpha Teknova went public with an initial public offering (IPO) on June 25, 2021.[6] On December 15 of the same year, it was added to the Nasdaq Biotechnology Index.[7]
In August 2023, the company opened a new modular Good Manufacturing Practice (GMP)-certified manufacturing facility in Hollister, California. This expansion increased the site to more than 200,000 square feet, enhancing its production capacity and adding modern capabilities.[8]
Industries and Products
[edit]Alpha Teknova serves several key areas in biotechnology:
- Bioproducts: Supplies reagents and materials for gene therapy, vaccine development, plasmid production, monoclonal antibodies (mAbs), and cell therapy.
- Molecular Diagnostics: Offers products for the amplification, extraction, sequencing, and analysis of DNA and RNA. This includes buffers and enzymes for reverse transcription (RT) and products for protein expression and analysis.
- Synthetic Biology: Provides culture media and agar plates for the growth of microorganisms and modified yeasts, as well as systems for culturing and maintaining mammalian cell lines.[9]
Recent Developments
[edit]- September 27, 2023: Launched the latest version of its patented AAV-Tek™ AEX buffer screening kit for serotype identification of AAV6, along with a reagent kit to support each stage of the plasmid manufacturing process.[10]
- May 7, 2024: Introduced Build-Tek™ Solutions, a customizable product configurator designed to meet the need for rapid recovery using high-quality buffers during the early stages of therapy development. Also announced the availability of the newest product from its AAV-Tek™ Solutions line—the AAV-Tek stabilizer—which enhances recovery and protects the integrity of capsids throughout the purification process.[11]
- August 16, 2024: Launched two new products: Express-Tek™, which allows customers to bring their products to market in days instead of weeks, significantly reducing lead times; and RUO+, which enables customers to scale efficiently from discovery through process development into clinical manufacturing.[12]
References
[edit]- ^ Alpha Teknova Corporate Profile
- ^ "Our Story | Teknova". teknova.com. Retrieved 2024-09-26.
- ^ Alpha Teknova Board Members
- ^ "Insider News and Rankings | Latest Movements | Marketscreener". www.marketscreener.com. Retrieved 2024-09-26.
- ^ Alpha Teknova’s ISO 13485:2016 certificate
- ^ "Teknova Announces Pricing of its Upsized Initial Public Offering". Yahoo Finance. 2021-06-25. Retrieved 2024-09-26.
- ^ "Teknova to Join the Nasdaq Biotechnology Index". Yahoo Finance. 2021-12-15. Retrieved 2024-09-26.
- ^ "Teknova's Life Sciences Reagents Manufacturing Facility, Hollister, California, USA". Pharmaceutical Technology. Retrieved 2024-09-26.
- ^ "Industries | Teknova". teknova.com. Retrieved 2024-09-26.
- ^ "Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development". Sept. 27, 2023.
- ^ "Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development". May 07, 2024.
- ^ "Teknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy Development". Aug. 13, 2024.